Active pharmaceutical ingredient (API) supplier PharmaZell, and Novasep, a contract development and manufacturing organization (CDMO) focused on complex small molecules and ADCs, are merging following negotiations begun in September 2021. This deal results in a CDMO focusing on manufacturing APIs.
Novasep’s assets, capabilities, experience and expertise complement those of PharmaZell. Combining the two businesses results in a company with a presence in Europe, the U.S. and India. The combined business will generate nearly €500 million of revenues and employ more than 2,000 employees across ten production and R&D sites, with 7 in Europe, 2 in India and 1 in the U.S.